Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q4 2021 · 10-K
Revenue$0.00$0.00derived−100.0% vs Q4 2020 Net Income-$94.63M-$94.63MderivedN/M vs Q4 2020 EPS Diluted-$1.74-$1.74N/M vs Q4 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
Operating Incomederived-$104,827,000N/M Operating Cash Flowderived-$84,093,000N/M Free Cash Flowderived-$88,595,000N/M ended Dec 31, 2021 · filed Feb 24, 2022 · 55 d after period end